Small Molecules

16 May 2020 Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer’s Disease Does Not Meet Primary Endpoint
16 May 2020 Vividion Therapeutics to Present Data on Novel Covalent E3 Ligase Engager Supporting Broad Targeted Protein Degradation at 2020 AACR Annual Meeting
16 May 2020 Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
16 May 2020 Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting
16 May 2020 UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer
16 May 2020 U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma
16 May 2020 Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy
16 May 2020 FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
15 May 2020 Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor With Robust In Vivo Activity
14 May 2020 SciMount announces FDA approval of SMP-100's IND application for the treatment of Irritable Bowel Syndrome
14 May 2020 LG Chem Life Sciences Innovation Center Announces Data from Phase I Study of its Ulcerative Colitis Treatment LC51-0255
14 May 2020 Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective
14 May 2020 Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC® Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer
14 May 2020 Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma
13 May 2020 Sunovion Discontinues Dasotraline Program
12 May 2020 Minoryx Therapeutics doses first patient with leriglitazone in registration-enabling cALD NEXUS trial
12 May 2020 MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
12 May 2020 GENFIT: Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis
10 May 2020 Daewoong Pharmaceutical Unveils Phase 3 Clinical Data of Fexuprazan, A Novel Potassium-competitive Acid Blocker
10 May 2020 Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers
10 May 2020 LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
08 May 2020 Passage Bio Announces Expansion of Gene Therapy Collaboration with University of Pennsylvania
08 May 2020 HighTide Therapeutics Announces Positive Topline Results From Phase 2a Study of HTD1801 in NASH Patients
08 May 2020 Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19
07 May 2020 Enanta Announces Results of INTREPID Study of EDP-305 for the Treatment of Primary Biliary Cholangitis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up